Medicine in short supply

Published August 14, 2022

THAT rising import prices of pharmaceutical raw materials and increasing production costs of manufacturers have started to reflect in the shortage of several essential drugs that are used to treat life-threatening diseases and mental illnesses is quite disturbing. A report in this paper says at least 40 medicines have practically vanished from the shelves in parts of the country in recent weeks because most producers have stopped importing expensive ingredients due to the regulator’s refusal to jack up retail prices of their finished products. That would have helped them absorb the impact of the rupee devaluation and the surging costs of imported raw materials, energy and transportation. This is just the beginning. The market players have warned of more shortages if the producers’ prices are not raised to help them recoup their elevated production expenses. This unfolding crisis-like situation has been a long time in the making as the industry’s margins continue to shrink owing to escalation in production expenditure. Yet the Drug Regulatory Authority of Pakistan has taken no action to avert the pain that recent drug shortages are causing patients who are forced to either cut down on their daily doses or pay a much higher price to procure these medicines from the black market.

Drug pricing in Pakistan has always been a politically charged subject, resulting in overregulation of the industry. Tight government control over drug pricing often manifests itself in repeated shortages of essential medicines. It also constrains the industry’s expansion despite its huge export potential as it keeps the regulator from enforcing international quality standards. Many foreign companies have exited Pakistan due to shrinking returns on their investment. This must change. It is high time prices of medicines — barring life-saving drugs — were deregulated. Innovative approaches would have to be adopted to protect vulnerable groups, who should get free — rather than cheap — medicines. One way could be the imposition of a levy on the firms’ annual turnover for directly funding procurement of medicines for public-sector hospitals for free distribution among poor patients. This will force Drap to focus on its job of ensuring quality and preventing an influx of spurious and substandard products in the market. Other regional countries like India and Bangladesh have long ago deregulated their pharmaceutical industries. This has helped them grow their respective industries, enforce global quality standards, and expand into the American and European markets by attracting huge domestic and foreign investments. The competition among the producers has forced them to improve their technology and become efficient, which keeps drug prices affordable for the majority of people. If they can, Pakistan can too.

Published in Dawn, August 14th, 2022

Opinion

Editorial

The Musharraf enigma
Updated 06 Feb, 2023

The Musharraf enigma

The Musharraf era holds numerous lessons for Pakistan’s ruling elite, civilian and military.
Staying neutral
06 Feb, 2023

Staying neutral

THE Election Commission of Pakistan has what is perhaps one of the most thankless jobs in the country. The countless...
Wikipedia ban
06 Feb, 2023

Wikipedia ban

THE country was back in a familiar, dark place last week when the PTA blocked Wikipedia over the charge that it...
IMF’s firm stance
Updated 05 Feb, 2023

IMF’s firm stance

Pakistan needs to complete the review to stave off a default as well as to unlock inflows from other multilateral and bilateral lenders.
Grotesque bigotry
05 Feb, 2023

Grotesque bigotry

FREEDOM to profess one’s faith is guaranteed by the Constitution of Pakistan. However, for the country’s Ahmadi...
Kashmir reflections
05 Feb, 2023

Kashmir reflections

ASIDE from Kashmir Day, which the nation is observing today as an official holiday, there are a number of other days...